NeoGenomics, Inc. (NEO)

13,18 -0,24 (-1,79%) Alla chiusura: 04:00PM EDT

NeoGenomics, Inc.

9490 NeoGenomics Way
Fort Myers, FL 33912
United States
239 768 0600
https://www.neogenomics.com

Settore/i: Healthcare
Settore: Diagnostics & Research
Impiegati a tempo pieno: 2.100

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Christopher Michael Smith BSc	CEO & Director	2,86M	N/D	1963
Mr. Jeffrey S. Sherman M.B.A.	Chief Financial Officer	1,17M	N/D	1966
Mr. Vishal Sikri	President of Advanced Diagnostics	1,08M	N/D	1976
Ms. Melody Harris Esq., J.D.	President & COO of Informatics	1,4M	N/D	1967
Mr. Warren Stone	Chief Commercial Officer	1,42M	N/D	1973
Mr. Gregory D. Aunan	Chief Accounting Officer	N/D	N/D	1969
Ms. Kendra Sweeney	Vice President of Investor Relations & Communications	N/D	N/D	N/D
Ms. Alicia Olivo	Executive VP of Business Development, General Counsel & Corporate Secretary	N/D	N/D	1984
Mr. Hutan Hashemi J.D.	Chief Compliance Officer	N/D	N/D	1979
Dr. Derek Lyle M.D.	Chief Medical Officer	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.

Governance aziendale

L'ISS Governance QualityScore di NeoGenomics, Inc. al 1 giugno 2024 è 6. I criteri di valutazione fondamentali sono revisione: 4; Consiglio di Amministrazione: 3; diritti degli azionisti: 3; retribuzione: 10.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.